Cornea

CORE Saves Record Number of Lives in October Thanks to Region's Unprecedented Generosity

Retrieved on: 
Wednesday, November 8, 2023

PITTSBURGH, Nov. 8, 2023 /PRNewswire/ -- The Center for Organ Recovery & Education (CORE) announced today that October marked a new milestone for most organ and tissue donors in a single month throughout its service area, spanning western Pennsylvania, West Virginia and Chemung County, New York. The region saw a record number of lives Saved and Healed, fueled by the selflessness of donors and their families along with the tireless work of transplant teams, hospital partners and community volunteers.

Key Points: 
  • The region saw a record number of lives Saved and Healed, fueled by the selflessness of donors and their families along with the tireless work of transplant teams, hospital partners and community volunteers.
  • In total, 45 organ donors gave second chances to individuals on the waiting list for life-saving transplants, resulting in 113 total organs transplanted during October.
  • "This is a proud moment for everyone at CORE," said Susan Stuart, President and CEO of CORE.
  • One person can save the lives of eight by donating organs and heal the lives of 75 through tissue donation.

Lifeline of Ohio presents awards to champions of organ, eye and tissue donation

Retrieved on: 
Monday, October 30, 2023

Columbus, OH, Mar 30, 2021 (GLOBE NEWSWIRE) -- Lifeline of Ohio and the Donate Life community invites the public to come together on April 1 at 7:30 p.m. EST for a first-of-its-kind online musical celebration of life to kick off Donate Life Month. 

Key Points: 
  • “This event is a special reminder of the incredible collaboration throughout the donation process,” said Lifeline of Ohio CEO Andrew Mullins.
  • Lifeline of Ohio’s Rooted in Life campaign was also unveiled to showcase the effort to diminish disparities in the Black community surrounding donation and transplantation.
  • Several donation champion awards were presented to community partners who play vital roles throughout the donation process.
  • For more information about organ, eye and tissue donation, visit http://www.lifelineofohio.org

Centricity Vision Announces Commercial Launch of ZEPTOLink IOL Positioning System at AAO Conference

Retrieved on: 
Wednesday, November 1, 2023

CARLSBAD, Calif., Nov. 1, 2023 /PRNewswire/ -- Centricity Vision Inc., a global ophthalmic technology company, announced today the commercial launch of its ZEPTOLink IOL Positioning System™ at the American Academy of Ophthalmology (AAO) Annual Meeting, November 3-6 in San Francisco. The new platform seamlessly integrates the clinically proven ZEPTO precision pulse capsulotomy technology with any phacoemulsification (phaco) system to streamline cataract surgery.

Key Points: 
  • New Platform Integrates With All Phacoemulsification Systems,
    CARLSBAD, Calif., Nov. 1, 2023 /PRNewswire/ -- Centricity Vision Inc. , a global ophthalmic technology company, announced today the commercial launch of its ZEPTOLink IOL Positioning System™ at the American Academy of Ophthalmology (AAO) Annual Meeting, November 3-6 in San Francisco.
  • ZEPTO is the first and only device that creates an instantaneous capsulotomy with consistent, 360-degree intraocular lens (IOL) overlap for optimal lens positioning and improved outcomes.
  • Now with the phaco integration, ZEPTOLink is the next evolution helping to drive the future of automated refractive cataract surgery.
  • Following AAO, Centricity Vision will upgrade existing users of the prior ZEPTO system to ZEPTOLink while also onboarding new accounts.

iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

Retrieved on: 
Thursday, October 26, 2023

iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.

Key Points: 
  • iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.
  • Myopia generally first occurs in school-age children and progresses as the eye grows.
  • IVMED-85 is an experimental topical eye drop that is designed to be administered twice-daily to slow the progression of myopia in children.
  • Dr. Molokhia added that “The NIH and NEI have been extremely supportive of our topical eye drop for treatment of progressive myopia.

Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

Retrieved on: 
Tuesday, October 24, 2023

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
  • “The start of this trial is another important milestone in our goal of bringing this corneal endothelial cell therapy to millions of patients in need throughout the world.
  • The Phase 1 / 2 clinical trial (ABA-1, CLARA) is a prospective, multi-center, randomized, double masked, parallel-arm cell dose-ranging clinical trial in subjects with corneal edema secondary to corneal endothelial dysfunction.
  • This trial is designed to assess the safety, tolerability, and efficacy of AURN001 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

Retrieved on: 
Tuesday, October 24, 2023

NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.

Key Points: 
  • NATACYN® (natamycin ophthalmic suspension) 5%, a sterile antifungal for treating fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
  • ZERVIATE® (cetirizine ophthalmic solution) 0.24%, a histamine-1 (H1) receptor antagonist indicated for treating ocular itching associated with allergic conjunctivitis.
  • Harrow announced its acquisition of the U.S. commercial rights of these products in July of 2023.
  • To date, Harrow has been receiving profit transfers on these products; however, with the transfer of the NDAs completed, Harrow has launched these products in the U.S. under the Harrow name.

Orasis Pharmaceuticals Announces FDA Approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

Retrieved on: 
Wednesday, October 18, 2023

QLOSI is expected to be commercially available in the U.S. in the first half of 2024.

Key Points: 
  • QLOSI is expected to be commercially available in the U.S. in the first half of 2024.
  • "The FDA approval of QLOSI marks a tremendous milestone for Orasis as we continue our mission to provide a flexible treatment option for the millions of people in the U.S. living with presbyopia, or blurry near vision," said Elad Kedar, Chief Executive Officer of Orasis Pharmaceuticals.
  • "I am grateful to the Orasis team, our strategic partners, clinical investigators, and patients who participated in our clinical trials, all of whom made this achievement possible."
  • QLOSI (pronounced CLOH-see) is a prescription eye drop that can be used daily, or as needed, up to twice per day.

Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023

Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.

Key Points: 
  • Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV.
  • When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate.
  • Skin reactions occurred in 72% (all grades) of the 121 patients treated with PADCEV in combination with pembrolizumab in clinical trials.
  • The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash.

Heidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Retrieved on: 
Friday, October 13, 2023

Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.

Key Points: 
  • Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.
  • View the full release here: https://www.businesswire.com/news/home/20231013216160/en/
    “Building upon our previous CE-marking, we are thrilled that the ANTERION platform is now available to eye care providers across the U.S.,” said Arianna Schoess Vargas, Managing Director of Heidelberg Engineering GmbH.
  • Central to the ANTERION platform is the Imaging App, which was FDA cleared in November 2021.
  • For more information about ANTERION, visit our website or contact us directly.

World Sight Day is October 12, 2023 - HCP Cureblindness Shines Light on Avoidable Blindness and Its Mission to Help Individuals in Underserved Countries Retain and Regain Their Sight

Retrieved on: 
Thursday, October 5, 2023

Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.

Key Points: 
  • Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.
  • 90% of these individuals live in low-to-middle income countries, where poor nutrition and limited access to eye care can mean a life limited by needless blindness.
  • "This World Sight Day, HCP is shining a light on why avoidable blindness can – and must – be overcome," said K-T Overbey, HCP's Chief Executive Officer.
  • "This World Sight Day, everyone should learn the easy steps to help the millions who are blind or who have moderate-to-severe vision impairment."